3.215.190.193
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup

Study evaluates rate of implant bimatoprost biodegradation

Posted on

The estimated mean size of 10-µg bimatoprost implant (Durysta, Allergan) administered on Day 1 in phase 3 trials decreases according to an exponential function. This information can be used to predict the size of a single- or multiple implants in the anterior chamber and help determine the ideal timing for implant re-administration, according to a recent study presented at ARVO 2021.

Researchers evaluated the rate of biodegradation of the bimatoprost implant in two 20-month randomized, controlled in the phase 3 ARTEMIS clinical trials. The implant 10 µg is a biodegradable, intracameral implant that releases bimatoprost steadily for about 4 months to lower IOP and then converts to water and CO2. The polymers in the implant matrix may last longer. In the trials, 1 eye per patient with open-angle glaucoma or ocular hypertension was randomized to an intracameral 10- or 15-µg bimatoprost implant administered on Day 1, Weeks 16 and 32 or topical timolol 0.5% BID. Gonioscopy was used to estimated implant size as a percentage of the initial size. Data was pooled for the 10-µg implants placed on Day 1 in both trials for analysis.

For the 230 eyes included, the estimated mean percentage decrease in implant size from baseline was 24.1% at Week 28 and 80.2% at Week 52. The estimated mean rate of implant biodegradation was 3.7%/month through Week 28, 10.2%/month after Week 28 through Week 52, and 2.4%/month after Week 52 through Month 20. Further clinical studies are underway to further evaluate implant biodegradation and implant re-administration timing, the researchers said.

Reference
Brubaker JW, et al. Rate of bimatoprost implant biodegradation in the phase 3 ARTEMIS studies. Presented at: ARVO 2021.

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-